← Back to Clinical Trials
Recruiting NCT06531681

NCT06531681 Precision Radiotherapy for Tumours Using Magnetic Resonance-guided Linear Accelerator (MR-Linac)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06531681
Status Recruiting
Phase
Sponsor The Second Affiliated Hospital of Hainan Medical University
Condition Overall Response Rate
Study Type OBSERVATIONAL
Enrollment 3,000 participants
Start Date 2023-08-19
Primary Completion 2028-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type OBSERVATIONAL
Interventions
MR-Linac

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 3,000 participants in total. It began in 2023-08-19 with a primary completion date of 2028-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Aim to observe the application of MR-Linac for precision radiotherapy of tumours, analyse its therapeutic effect, toxic and side effects,Characteristics of dosimetric parameters etc.

Eligibility Criteria

Inclusion Criteria: * Patients are undergoing or have undergone imaging or treatment at the MR linac; * Age 18-75 years, male or female; * ECOG score 0-2, life expectancy \> 6 months; * Patients provide written informed consent. Exclusion Criteria: * Contraindications to MRI, such as claustrophobia and metallic or electronic implants incompatible with MRI; * The presence of severe comorbidities that, in the opinion of the investigator, · preclude the toleration or completion of radiotherapy; * Acute inflammatory disease requiring systemic therapy; * The presence of active infectious disease; * Pregnant women, nursing mothers, and patients planning to have children during the study period.

Contact & Investigator

Central Contact

junnv xu, doctor

✉ xujunnv@sina.com

📞 18208946196

Principal Investigator

yuecan zeng, doctor

PRINCIPAL INVESTIGATOR

The Second Affiliated Hospital of Hainan Medical University

Frequently Asked Questions

Who can join the NCT06531681 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Overall Response Rate. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06531681 currently recruiting?

Yes, NCT06531681 is actively recruiting participants. Contact the research team at xujunnv@sina.com for enrollment information.

Where is the NCT06531681 trial being conducted?

This trial is being conducted at Haikou, China.

Who is sponsoring the NCT06531681 clinical trial?

NCT06531681 is sponsored by The Second Affiliated Hospital of Hainan Medical University. The principal investigator is yuecan zeng, doctor at The Second Affiliated Hospital of Hainan Medical University. The trial plans to enroll 3,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology